Suven Pharmaceuticals announced that it has signed definitive agreements to acquire a 56% equity stake in NJ Bio, Inc. The $64.4 million deal includes both primary equity infusion and secondary acquisition. NJ Bio is a Contract Research, Development, and Manufacturing Organization (CRDMO) based in Princeton, New Jersey, specializing in antibody-drug conjugates (ADCs) and other advanced drug conjugates (XDCs), which are key segments in targeted therapeutics.
Read the full article: Suven Pharma to Acquire Majority Stake in US-Based NJ Bio //
Source: https://www.business-standard.com/markets/capital-market-news/suven-pharma-to-acquire-majority-stake-in-us-based-nj-bio-124120700540_1.html